Pamela J. Atherton

2.7k total citations
43 papers, 2.2k citations indexed

About

Pamela J. Atherton is a scholar working on Oncology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Pamela J. Atherton has authored 43 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 9 papers in Molecular Biology and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Pamela J. Atherton's work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer survivorship and care (10 papers). Pamela J. Atherton is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (10 papers) and Cancer survivorship and care (10 papers). Pamela J. Atherton collaborates with scholars based in United States, Canada and Germany. Pamela J. Atherton's co-authors include Jeff A. Sloan, Charles Erlichman, Alex A. Adjei, Joel M. Reid, Lorelei J. Hanson, Matthew M. Clark, Teresa A. Rummans, Paul D. Brown, Marlene H. Frost and Gail L. Gamble and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Pamela J. Atherton

43 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pamela J. Atherton United States 22 1.2k 714 368 280 262 43 2.2k
Ellen G. Feigal United States 21 1.5k 1.3× 735 1.0× 379 1.0× 147 0.5× 141 0.5× 43 2.8k
V. Trillet-Lenoir France 27 1.5k 1.2× 308 0.4× 356 1.0× 233 0.8× 263 1.0× 105 2.4k
Henrike E. Karim‐Kos Netherlands 27 1.4k 1.1× 356 0.5× 582 1.6× 315 1.1× 124 0.5× 67 2.7k
Gary L. Goldberg United States 38 1.2k 1.0× 723 1.0× 429 1.2× 329 1.2× 173 0.7× 211 4.3k
David M. Mintzer United States 22 545 0.5× 439 0.6× 477 1.3× 180 0.6× 97 0.4× 60 2.3k
Paul Harden United Kingdom 30 1.1k 0.9× 473 0.7× 386 1.0× 404 1.4× 271 1.0× 96 3.4k
Jane Bryce Italy 19 978 0.8× 355 0.5× 408 1.1× 156 0.6× 91 0.3× 41 1.8k
Richard S. Ungerleider United States 18 756 0.6× 639 0.9× 286 0.8× 712 2.5× 172 0.7× 37 2.3k
Sarah M. Temkin United States 31 868 0.7× 719 1.0× 247 0.7× 351 1.3× 246 0.9× 131 3.0k
Anand B. Karnad United States 24 1.0k 0.8× 805 1.1× 363 1.0× 185 0.7× 96 0.4× 75 2.5k

Countries citing papers authored by Pamela J. Atherton

Since Specialization
Citations

This map shows the geographic impact of Pamela J. Atherton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela J. Atherton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela J. Atherton more than expected).

Fields of papers citing papers by Pamela J. Atherton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela J. Atherton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela J. Atherton. The network helps show where Pamela J. Atherton may publish in the future.

Co-authorship network of co-authors of Pamela J. Atherton

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela J. Atherton. A scholar is included among the top collaborators of Pamela J. Atherton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela J. Atherton. Pamela J. Atherton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Al‐Kali, Aref, Raoul Tibes, Pamela J. Atherton, et al.. (2023). A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. American Journal of Hematology. 98(3). 472–480. 5 indexed citations
3.
Al‐Kali, Aref, Ibrahim Aldoss, Pamela J. Atherton, et al.. (2023). A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia. Cancer Medicine. 12(23). 21229–21239. 6 indexed citations
4.
5.
Villasboas, José C., Justin Kline, Aleksandr Lazaryan, et al.. (2022). Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).. Journal of Clinical Oncology. 40(17_suppl). LBA7564–LBA7564. 1 indexed citations
6.
Bennani, N. Nora, Levi Pederson, Pamela J. Atherton, et al.. (2019). A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood. 134(Supplement_1). 467–467. 27 indexed citations
7.
Bakkum‐Gamez, Jamie N., Matthew S. Block, Deepak Upreti, et al.. (2018). Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFNβ-NIS (Voyager-V1™) in Stage IV or recurrent endometrial cancer. Cancer Research. 78(13_Supplement). CT072–CT072. 4 indexed citations
8.
Atherton, Pamela J., Deborah Watkins Bruner, Carolyn Gotay, et al.. (2015). The Complementary Nature of Patient-Reported Outcomes and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591). Journal of Pain and Symptom Management. 50(4). 470–479.e9. 17 indexed citations
9.
Brown, Lindsay C., Pamela J. Atherton, M.A. Neben-Wittich, et al.. (2013). Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Supportive Care in Cancer. 21(10). 2869–2877. 4 indexed citations
10.
11.
Barton, Debra L., Angelina D. Tan, Pamela J. Atherton, Mary Louise Z. Collins, & Jeff A. Sloan. (2011). The menopausal experience of premenopausal women receiving adjuvant chemotherapy for breast cancer. 1 indexed citations
12.
Frost, Marlene H., Teresa A. Rummans, Mashele Huschka, et al.. (2007). Role of a Medical Social Worker in Improving Quality of Life for Patients with Advanced Cancer with a Structured Multidisciplinary Intervention. Journal of Psychosocial Oncology. 25(4). 105–119. 49 indexed citations
13.
Brown, Paul D., Matthew M. Clark, Pamela J. Atherton, et al.. (2006). Will Improvement in Quality of Life (QOL) Impact Fatigue in Patients Receiving Radiation Therapy for Advanced Cancer?. American Journal of Clinical Oncology. 29(1). 52–58. 64 indexed citations
14.
Mesa, Ruben A., Joyce Niblack, Martha Wadleigh, et al.. (2006). The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet Based Survey of 1179 MPD Patients.. Blood. 108(11). 4872–4872. 27 indexed citations
15.
Galanis, Evanthia, Scott H. Okuno, Antonio G. Nascimento, et al.. (2005). Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy. 12(5). 437–445. 130 indexed citations
16.
Atherton, Pamela J., Andrea M. Nibbe, Cristine Allmer, et al.. (2003). What Happened to All the Patients? Event Charts for Summarizing Individual Patient Data and Displaying Clinically Significant Changes in Quality of Life Data. Drug Information Journal. 37(1). 11–21. 5 indexed citations
17.
Adjei, Alex A., Gary A. Croghan, Charles Erlichman, et al.. (2003). A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.. PubMed. 9(7). 2520–6. 40 indexed citations
18.
Goldberg, Richard M., Scott H. Kaufmann, Pamela J. Atherton, et al.. (2002). A phase I study of sequential irinotecan and5-fluorouracil/leucovorin. Annals of Oncology. 13(10). 1674–1680. 11 indexed citations
19.
Adjei, Alex A., Charles Erlichman, J. Nathan Davis, et al.. (2000). A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.. PubMed. 60(7). 1871–7. 201 indexed citations
20.
Adjei, Alex A., Cheri E. Klein, Helen Kastrissios, et al.. (2000). Phase I and Pharmacokinetic Study of Irinotecan and Docetaxel in Patients With Advanced Solid Tumors: Preliminary Evidence of Clinical Activity. Journal of Clinical Oncology. 18(5). 1116–1116. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen G. Feigal Breakdown of academic impact, for papers by V. Trillet-Lenoir Breakdown of academic impact, for papers by Henrike E. Karim‐Kos Breakdown of academic impact, for papers by Gary L. Goldberg Breakdown of academic impact, for papers by David M. Mintzer Breakdown of academic impact, for papers by Paul Harden Breakdown of academic impact, for papers by Jane Bryce Breakdown of academic impact, for papers by Richard S. Ungerleider Breakdown of academic impact, for papers by Sarah M. Temkin Breakdown of academic impact, for papers by Anand B. Karnad
Rankless by CCL
2026